AbbVie Inc. (ABBV) reported a 68% jump in earnings for the third quarter helped by sales growth from Humira, Imbruvica, and HCV. The top and bottom lines came in above analysts’ expectations. The company also raised its adjusted EPS guidance for the full year 2018. Following this, the stock inched up over 2% in the … Continue reading AbbVie Q3 profit jumps 68%, beats estimates